12月2日北京时间晚9点，博沃生物受邀出席世界卫生组织（WHO）为博沃新冠疫苗项目召开的专题Webinar，向各国药监机构官员介绍了博沃新冠疫苗产品BravoCoVac®。

At 1PM UTC December 2nd, honorly invited by World Health Organization (WHO), BravoVax attended the Dedicated Webinar for BravoVax COVID-19 Vaccine, formally introducing its COVID-19 vaccine, BravoCoVac®, to the NRAs across the world!

作为一家尚未盈利的研发型企业，博沃生物厚积薄发，凭借新冠疫苗项目具备优势的抗原设计、全面完善的工艺开发，再到令人鼓舞的动物实验数据，受到了WHO的关注与青睐。

As a start-up R&D company, BravoVax received sustainable attention from WHO by the superior antigen design, comprehensive process development and encouraging animal study data of its novel COVID-19 vaccine.

博沃生物CEO吴克博士在Webinar上做专题演讲，介绍了BravoCoVac®设计路径、临床前研究数据、稳定性研究等，国际顾问介绍了BravoCoVac®临床开发方案，得到药监机构参会人员的积极反馈。吴克博士及其团队与外部顾问逐一回复了与会人员的在线留言及现场提问。

Dr. Wu Ke, CEO of BravoVax, gave a speech on the Webinar, introducing the product design route, preclinical study and stability study data of BravoCoVac®, and our external consultant, Dr. Ben Greener, presented the Clinical Development Plans for BravoCoVac®, winning positive feedbacks from the participants. Dr. Wu and his team as well as external consultant responded to all the online and on-site questions from the regulatory officers.

自博沃生物创立之初，即以提供质优价廉的疫苗、造福于全球健康事业为己任。我们不忘初心，期盼更多的人能够用上博沃疫苗，让全球疫情早日得到控制！

Ever since the establishment of BravoVax, it has a vision to be a global supplier of high-quality and affordable vaccines. Following this dream, we make great endeavors to develop the COVID-19 vaccine, expecting more people in the world could get access to our novel vaccines, thus contributing to the control of the pandemic!

免责声明：本文所涉及内容仅作分享及交流，不作为投资意见。我们对文中观点保持中立。同时，非本公众号原创文章，我们会尽量标明准确出处，感谢原作者辛苦创作，如有侵权，请告知，我们将在第一时间核实并处理,请联系：028-85215588。